Figure 5
Mini-CLL score for B-LPDs and the generation of the diagnostic discriminant to differentiate between CLL and MCL. The mini-CLL score was derived from the CD160FCA, with one point for each marker, CD5, CD23, and CD160. (A) The mini-CLL score within the test cohort (n = 811). (B) The mini-CLL score within the validation cohort (n = 163). (C) The diagnostic discriminant was generated by multiplying the mini-CLL score and CD23r variables. CLL versus MCL (*P < .0001), HCL (**P = .0002), and CD5+ chronic B-cell malignancies (***P < .0001).

Mini-CLL score for B-LPDs and the generation of the diagnostic discriminant to differentiate between CLL and MCL. The mini-CLL score was derived from the CD160FCA, with one point for each marker, CD5, CD23, and CD160. (A) The mini-CLL score within the test cohort (n = 811). (B) The mini-CLL score within the validation cohort (n = 163). (C) The diagnostic discriminant was generated by multiplying the mini-CLL score and CD23r variables. CLL versus MCL (*P < .0001), HCL (**P = .0002), and CD5+ chronic B-cell malignancies (***P < .0001).

Close Modal

or Create an Account

Close Modal
Close Modal